Peters HA - Search Results

1

The prognostic value of BCAR1 in patients with primary breast cancer.

Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC. Dorssers LC, et al. Among authors: peters ha. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6194-202. doi: 10.1158/1078-0432.CCR-04-0444. Clin Cancer Res. 2004. PMID: 15448007

2

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.

Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brünner N, Foekens JA. Schrohl AS, et al. Among authors: peters ha. Clin Cancer Res. 2004 Apr 1;10(7):2289-98. doi: 10.1158/1078-0432.ccr-03-0360. Clin Cancer Res. 2004. PMID: 15073104

3

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.

Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA. Meijer-van Gelder ME, et al. Among authors: peters ha. Cancer Res. 2004 Jul 1;64(13):4563-8. doi: 10.1158/0008-5472.CAN-03-3848. Cancer Res. 2004. PMID: 15231667

4

Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue.

Grebenchtchikov N, Brinkman A, van Broekhoven SP, de Jong D, Geurts-Moespot A, Span PN, Peters HA, Portengen H, Foekens JA, Sweep CG, Dorssers LC. Grebenchtchikov N, et al. Among authors: peters ha. Clin Chem. 2004 Aug;50(8):1356-63. doi: 10.1373/clinchem.2003.029868. Clin Chem. 2004. PMID: 15277346 Free article.

5

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA. Berns EM, et al. Clin Cancer Res. 2003 Apr;9(4):1253-8. Clin Cancer Res. 2003. PMID: 12684392

6

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG. Foekens JA, et al. Among authors: peters ha. Cancer Res. 1992 Nov 1;52(21):6101-5. Cancer Res. 1992. PMID: 1394237

7

Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.

Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JG. Foekens JA, et al. Among authors: peters ha. Cancer Res. 1989 Nov 1;49(21):5823-8. Cancer Res. 1989. PMID: 2676151

8

Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.

Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG, Kramer MD. Foekens JA, et al. Among authors: peters ha. Cancer Res. 1995 Apr 1;55(7):1423-7. Cancer Res. 1995. PMID: 7882345

9

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG. Foekens JA, et al. Among authors: peters ha. J Clin Oncol. 1994 Aug;12(8):1648-58. doi: 10.1200/JCO.1994.12.8.1648. J Clin Oncol. 1994. PMID: 8040677

10

Prognostic significance of cathepsins B and L in primary human breast cancer.

Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. Foekens JA, et al. Among authors: peters ha. J Clin Oncol. 1998 Mar;16(3):1013-21. doi: 10.1200/JCO.1998.16.3.1013. J Clin Oncol. 1998. PMID: 9508185

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters